Multicancer Screening Market by Sample (Blood, Saliva & Buccal Swab, Tissue), Test Type (In-vitro diagnostics (IVDs), Laboratory Developed Tests (LDTs)), Technology, Cancer Type, End User - Global Forecast 2024-2030

Multicancer Screening Market by Sample (Blood, Saliva & Buccal Swab, Tissue), Test Type (In-vitro diagnostics (IVDs), Laboratory Developed Tests (LDTs)), Technology, Cancer Type, End User - Global Forecast 2024-2030


The Multicancer Screening Market size was estimated at USD 1.13 billion in 2023 and expected to reach USD 1.24 billion in 2024, at a CAGR 9.30% to reach USD 2.11 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multicancer Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multicancer Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include AnchorDx Medical Co., Ltd., Anpac Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Grail, LLC by Illumina, Inc., Guardant Health, Inc., HLTH, INC., Lucence Health Inc., Micronoma, INC., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Sample

Blood

Saliva & Buccal Swab

Tissue
Test Type

In-vitro diagnostics (IVDs)

Laboratory Developed Tests (LDTs)
Technology

Fluorescence In-Situ Hybridization (FISH)

Immunohistochemistry (IHC)

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)
Cancer Type

Brain/Nervous System

Breast & Gynecologic

Endocrine

Gastrointestinal

Genitourinary

Hematological Malignancies

Lung

Sarcoma

Skin
End User

Academic & Research Institutions

Diagnostic & Clinical Laboratories

Hospitals
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multicancer Screening Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multicancer Screening Market?
3. What are the technology trends and regulatory frameworks in the Multicancer Screening Market?
4. What is the market share of the leading vendors in the Multicancer Screening Market?
5. Which modes and strategic moves are suitable for entering the Multicancer Screening Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Multicancer Screening Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer disease and rising aging population
5.1.1.2. Surge in demand for enhanced early detection procedures of cancers
5.1.1.3. Several government initiatives promoting multicancer screening in healthcare facilities
5.1.2. Restraints
5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
5.1.3. Opportunities
5.1.3.1. Potential utilization of liquid biopsy and rising multi-cancer detection (MCD) research centers
5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
5.1.4. Challenges
5.1.4.1. Concern associated with adequate safety and efficacy data and variability in test performance
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Multicancer Screening Market, by Sample
6.1. Introduction
6.2. Blood
6.3. Saliva & Buccal Swab
6.4. Tissue
7. Multicancer Screening Market, by Test Type
7.1. Introduction
7.2. In-vitro diagnostics (IVDs)
7.3. Laboratory Developed Tests (LDTs)
8. Multicancer Screening Market, by Technology
8.1. Introduction
8.2. Fluorescence In-Situ Hybridization (FISH)
8.3. Immunohistochemistry (IHC)
8.4. Next-Generation Sequencing (NGS)
8.5. Polymerase Chain Reaction (PCR)
9. Multicancer Screening Market, by Cancer Type
9.1. Introduction
9.2. Brain/Nervous System
9.3. Breast & Gynecologic
9.4. Endocrine
9.5. Gastrointestinal
9.6. Genitourinary
9.7. Hematological Malignancies
9.8. Lung
9.9. Sarcoma
9.10. Skin
10. Multicancer Screening Market, by End User
10.1. Introduction
10.2. Academic & Research Institutions
10.3. Diagnostic & Clinical Laboratories
10.4. Hospitals
11. Americas Multicancer Screening Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Multicancer Screening Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Multicancer Screening Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AnchorDx Medical Co., Ltd.
15.1.2. Anpac Bio-Medical Science Co., Ltd.
15.1.3. Burning Rock Biotech Limited
15.1.4. Caris Life Sciences
15.1.5. Delfi Diagnostics, Inc.
15.1.6. Elypta AB
15.1.7. EpiCypher, Inc.
15.1.8. Epigenomics AG
15.1.9. Exact Sciences Corporation
15.1.10. Foundation Medicine, Inc.
15.1.11. Freenome Holdings, Inc.
15.1.12. Grail, LLC by Illumina, Inc.
15.1.13. Guardant Health, Inc.
15.1.14. HLTH, INC.
15.1.15. Lucence Health Inc.
15.1.16. Micronoma, INC.
15.1.17. MiRXES Pte Ltd.
15.1.18. Myriad Genetics, Inc.
15.1.19. Natera, Inc.
15.1.20. Naveris
15.1.21. StageZero Life Sciences. Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
FIGURE 3. MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MULTICANCER SCREENING MARKET DYNAMICS
FIGURE 7. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
FIGURE 8. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
FIGURE 10. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 12. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 14. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings